MedPath

Sucralfate

Generic Name
Sucralfate
Brand Names
Carafate, Sulcrate
Drug Type
Small Molecule
Chemical Formula
C12H35Al9O55S8
CAS Number
54182-58-0
Unique Ingredient Identifier
XX73205DH5
Background

Sucralfate is a medication that is widely used to prevent and treat a number of diseases in the gastrointestinal tract such as duodenal ulcers , gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia . It is considered a cytoprotective agent, protecting cells in the gastrointestinal tract from damage caused by agents such as gastric acid, bile salts, alcohol, and acetylsalicylic acid (aspirin), among other substances .

Sucralfate has been shown to be a well-tolerated and safe drug. It is sold under many brands and is available in both tablet and suspension forms. It was approved by the FDA 1982 in tablet form, and in 1994 for the suspension form .

Indication

The sucralfate suspension and tablet are used for the treatment of active duodenal ulcer for up to 8 weeks. The tablet form may be used at a lower dose for healed duodenal ulcers, for the purpose of maintaining healing and preventing recurrence .

Sucralfate is also used in the prevention and/or treatment of gastro-esophageal reflux disease (GERD), gastritis, peptic ulcer disease, stress ulcer, in addition to dyspepsia .

Associated Conditions
Dyspepsia, Gastric Ulcer, Gastritis, Gastro-esophageal Reflux Disease (GERD), Healing, Mucositis, Peptic Ulcer, Stress Ulcers, Active Duodenal ulcer
Associated Therapies
Anti-platelet Therapy

Combined Therapy in Radiation Proctopathy

Phase 4
Completed
Conditions
Chronic Radiation Proctitis
Interventions
Drug: Sucralfate
Drug: Placebo
First Posted Date
2012-06-07
Last Posted Date
2012-06-07
Lead Sponsor
Maria Sklodowska-Curie National Research Institute of Oncology
Target Recruit Count
122
Registration Number
NCT01613534
Locations
🇵🇱

Department of Gastroenterology and Hepatology, Medical Center for Postgraduate Education and Department of Gastroenterology, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Mazowieckie, Poland

A Clinico-Bacteriological Study and Effect of Stress Ulcer Prophylaxis on Occurrence of Ventilator Associated Pneumonia

Phase 4
Completed
Conditions
Ventilator Associated Pneumonia
Etiological Organisms
Antimicrobial Drug Susceptibility Pattern
Stress Ulcer Prophylaxis
Interventions
First Posted Date
2008-06-20
Last Posted Date
2008-06-20
Lead Sponsor
Maulana Azad Medical College
Target Recruit Count
50
Registration Number
NCT00702871
Locations
🇮🇳

Maulana Azad Medical College and Lok Nayak Hospital, Delhi, India

© Copyright 2025. All Rights Reserved by MedPath